This month, Sentara Health and Macon & Joan Brock Virginia Health Sciences at Old Dominion University launched the ...
Clarametyx reports progress on study of antibody therapy CMTX-101 for infections associated with CF, to begin phase 2a portion of the trial: Columbus, Ohio Saturday, October 19, 2 ...
AMIVAS Ireland Ltd (AMIVAS), a biopharmaceutical company focused on developing, commercialising, manufacturing and ...
By Dr. Joseph Kim University of Kentucky Liver cancer is the sixth leading cause cancer death in the U.S. The most common ...
Urinary tract infections (UTIs ... Newer agents are now available for the treatment of UTI among older adults, targeting both the usual and the multiresistant uropathogens. Rational use of ...
Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
Ear, Nose, and Throat doctors are concerned about rising cases of hearing loss among Nigerians amid an acute shortage of ...
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...
Zacks.com on MSN2d
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority ReviewGSK plc GSK announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, ...
"It is of particular concern now because, as these viruses circulate together, they can put pressure on the NHS due to a ...
Gentle nasal spray vaccines against COVID, the flu and RSV are coming. They may work better than shots in the arm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback